KAF 156

Drug Profile

KAF 156

Alternative Names: GNF156; KAF-156

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antimalarials; Imidazoles; Piperazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vivax malaria

Most Recent Events

  • 29 May 2017 Novartis plans a phase II trial for Falciparum malaria (Combination therapy, In children, In adolescents, In adults, In elderly) (NCT03167242)
  • 10 Mar 2017 Phase-II development for Falciparum malaria and Vivax malaria is ongoing in Thailand and Vietnam (PO)
  • 15 Jun 2016 Novartis and Medicines for Malaria Venture expand collaboration to co-develop KAF 156
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top